Orforglipron
First once-daily oral non-peptide GLP-1. Brand-only, launched via LillyDirect at $149/mo in 2026.
A small-molecule GLP-1 receptor agonist that survives digestion, so it works as a simple daily pill without the fasting-and-water rules oral semaglutide (Rybelsus) requires. Reached its FDA decision date April 10, 2026. No compounded versions exist because it's a novel patented molecule.